← Back to headlines
Glaukos Outlines 2026 Net Sales Guidance
Glaukos has provided its financial outlook for 2026, projecting net sales between $680 million and $700 million, with iDose TR sales expected to reach $275 million to $280 million.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
